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Title: Gout characteristics associate with depression, but not anxiety, in primary care: 
baseline findings from a prospective cohort study 
 
Abstract  
Objectives: To determine the prevalence of anxiety and depression in gout, examine 
associations between gout characteristics and these comorbidities and determine the 
role of allopurinol in any such relationships. 
Method: As part of a prospective cohort study, a baseline questionnaire was sent to 
1,805 participants with gout aged ≥18 years from UK primary care. Participants had a 
gout diagnosis or prescriptions for allopurinol or colchicine in their medical records 
two years prior to baseline. Prevalence of anxiety was defined using the Generalised 
Anxiety Disorder questionnaire and depression using the Patient Health Questionnaire.  
Logistic regression was used to examine any association between gout characteristics 
(12-month attack frequency, oligo/polyarticular gout and gout duration) and the 
presence of anxiety or depression. Crude and adjusted associations were reported as 
Odds Ratios (OR) and 95% Confidence Intervals (CI). Adjusted gout characteristics were 
stratified by allopurinol use. 
Results: 1,184 participants responded to baseline (65.6%).  Prevalence of anxiety and 
depression were 10.0% and 12.6% respectively. There was no association between gout 
characteristics and anxiety. However, there was an association between attack 
frequency and depression amongst those gout patients using allopurinol (2.87 (1.2 to 
6.6)) and also between oligo/polyarticular gout and depression (2.01 (1.2 to 3.3)), 
irrespective of allopurinol use (2.09 (1.1 to 4.0)) or not (2.64 (1.0 to 6.8)).  
Conclusion: Patients experiencing frequent gout attacks or attacks in multiple joints are 
likely to experience depressive symptoms, even when using allopurinol. Depression 
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may influence medication adherence and participation in routine reviews, hence 
impacting adversely on gout management outcomes.  
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Introduction 
Gout is experienced by 2.5% of UK adults, making it the most common form of 
inflammatory arthropathy [1]. The primary risk factor for gout is an elevated serum 
urate level (hyperuricaemia), leading to monosodium urate (MSU) crystal deposition in 
and around joints, acute attacks of crystal synovitis and progressive joint damage [2]. 
Long-term treatment of gout involves using urate-lowering therapies (ULT), typically 
the xanthine oxidase inhibitor allopurinol [3]. 
Comorbidity is common in people with gout [4] and whilst the association with physical 
conditions has been widely investigated [5-7], research into the potential association 
between gout and psychological comorbidity (including anxiety and depression) 
remains limited. In particular there is sparse information on the prevalence of either 
anxiety or depression in gout patients in primary care, the setting where the majority of 
gout patients are managed and treated [8]. A small study of 50 gout patients undertaken 
in a Singapore Rheumatology department reported the prevalences of anxiety and 
depression, defined using the Hospital Anxiety and Depression Scale (HADS), to be 6% 
and 20% respectively [9].  The prevalence of depression (defined using the Patient 
Health Questionnaire (PHQ-9)) in adults aged 60 years or older with gout was 13.5% in 
the 2009-2010 National Health and Nutrition Examination Survey (NHANES) study, an 
estimate that was similar to that in the general population [10].  
We have previously examined the incidence rate of general practice consultation for 
anxiety and depression in gout patients in UK primary care [11]. In this population, we 
found no association between a diagnosis for gout and a subsequent consultation for 
these psychological comorbidities, when compared to primary care consulters matched 
by age, gender, year of consultation and general practice. However, this research was 
based on historical medical consultation for either anxiety or depression, both of which 
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are typically under-reported and under-diagnosed in general practice [12, 13]. 
Furthermore, owing to the nature of medical consultation data, no consideration of 
specific gout characteristics was possible, which have been shown to influence the 
psychological quality of life in gout patients [14].  
Previous research from English primary care and US secondary care populations found 
little influence of gout on psychological health, when compared to the influence on 
physical health [15-17]. However, when classification by gout characteristics was 
applied, such as by the number of painful joints [18], number of attacks in a 12-month 
period [14, 18-20] or disease duration [20], associations were found between gout and  
poorer general psychological health (as measured using the SF12 or SF36). This 
suggests that different gout characteristics may be important in identifying those 
patients more likely to experience poorer psychological health. However, it remains 
unclear whether the prevalence of anxiety and depression is associated with specific 
gout characteristics in UK primary care. The only paper to have considered the 
association between gout and psychological comorbidity was conducted by Khanna et al 
in a US secondary care sample. They found the prevalence of depression, determined 
from record review, to be greater in patients experiencing ≥2 flares in a 12-month 
period, even in patients treated with ULT [21]. 
The specific objectives of this study were i) to establish the prevalence of anxiety and 
depression amongst UK primary care gout patients, ii) to investigate the association 
between gout characteristics and anxiety and depression and iii) to examine the role of 
allopurinol use on any association with these psychological comorbidities. 
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Patients and methods 
Study design and population 
The study uses baseline data from a prospective primary care-based cohort study of 
people with gout [22]. Gout patients aged 18 years and older were recruited from 20 
research-active General Practices across the West Midlands, UK. Participants were 
selected based on the presence of Read codes for a previous consultation for gout or a 
prescription of allopurinol or colchicine in the electronic medical records within the two 
years preceding the baseline questionnaire.  Participants were mailed a postal 
questionnaire, with a two-staged reminder system in place for initial non-responders. 
With participant consent, questionnaire data were linked to participants’ medical 
records. Approval was obtained from the North West – Liverpool East Research Ethics 
Committee (Ref no: 12/NW/0297). 
 
Baseline survey measures 
The prevalence of anxiety and depression within the gout sample was assessed using 
two validated measures included in the baseline questionnaire. Anxiety status was 
determined using the Generalised Anxiety Disorder (GAD-7) questionnaire [23]. The 
GAD-7 consists of seven questions designed to identify cases of generalised anxiety 
disorder. Depression was assessed using the Patient Health Questionnaire (PHQ-9) [24], 
a nine-question measure developed for use in primary care to identify the presence of 
depression. The GAD-7 and PHQ-9 have both been shown to be capable of screening for 
their respective conditions and are valid measures of clinically diagnosed anxiety and 
depression [23, 24]. Scores of <10 represent ‘no anxiety’ or ‘no depression’ and scores 
of ≥10 represent the presence of anxiety or depression for each measure [23, 24].  
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The baseline questionnaire also collected data on age, gender, body mass index (BMI) 
and deprivation status. BMI was calculated from self-reported weight and height and 
deprivation status was assessed using the Indices of Multiple Deprivation (IMD), which 
is a neighbourhood level deprivation measure [25]. Other data collected included the 
frequency of alcohol consumption and self-reported comorbidities including 
hypertension, hyperlipidaemia, diabetes mellitus, angina, myocardial infarction, kidney 
stones, transient ischaemic attack, kidney failure or stroke. 
Gout-specific characteristics recorded included: the frequency of gout attacks in the last 
12 months, whether gout had ever been experienced in more than one joint at the same 
time (oligo/polyarticular gout), the age at which the diagnosis of gout had been made 
(gout duration), whether the participant was currently experiencing a gout attack, and 
whether the patient was currently using allopurinol. 
 
Statistical analysis 
The characteristics of the study sample were initially summarised using descriptive 
statistics. The mean age (Standard Deviation (SD)) and gender were reported. IMD was 
categorised into tertiles (the least deprived, mid-deprived and most deprived). BMI was 
categorised by those with a score i) <25.0 (healthy weight), ii) 25.0-29.9 (overweight), 
iii) 30.0-34.9 (obese) or iv) ≥35.0 (severely obese). The frequency with which alcohol 
was consumed was categorised as ; i) never, ii) occasionally, iii) 1-3 times per month, iv) 
1-2 times a week, v) 3-4 times a week or vi) daily/almost daily.   
The GAD-7 and PHQ-9 were reported as the proportion of respondents with or without 
anxiety symptoms, or with or without depression symptoms, by dichotomising each 
measure into either a score of <10 (condition not present) or ≥10 (condition present) 
[23, 24]. Subsamples with anxiety or depression were not mutually exclusive and the 
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same patient could be included in each of these two comorbid disease groups. 
Frequency of gout attacks in the last 12 months was categorised by 0, 1-2 or ≥3 attacks. 
Use of allopurinol and history of oligo/polyarticular attacks were each dichotomised 
into ‘yes’ or ‘no’. Gout duration was calculated by subtracting the age at diagnosis from 
the participant’s current age and was categorised into quartiles as; ≤2 years, 3-8, 9-17 
or 18≥ or more years.  
Logistic regression analysis (conducted using STATA, version 12), was used to assess 
the association between the gout characteristics of i) frequency of gout attacks, ii) 
oligo/polyarticular gout and iii) disease duration, with the presence of anxiety and 
depression symptoms. Associations were reported as Odds Ratios (OR) with 95% 
Confidence Intervals (CI) between these three gout characteristic and the presence of 
either anxiety or depression symptoms. Each association was initially examined as a 
crude analysis, then initially adjusted for age, gender and deprivation status, followed 
by a further stage of additional adjustment for BMI, comorbidities, alcohol consumption 
and gout characteristics. Adjustment for gout characteristics varied for each analysis 
depending on which characteristic was the focus. For example, frequency of gout attacks 
was adjusted for oligo/polyarticular gout and duration of gout.; oligo/polyarticular gout 
was adjusted for frequency of gout attacks and duration of gout and so on. All gout 
characteristics were adjusted for a current gout attack, Finally, once each of the three 
gout characteristics had been adjusted they were stratified by ‘use of allopurinol’.   
 
Results 
Sample characteristics  
Of the 1,805 gout patients mailed the baseline questionnaire, 1,184 responded (65.6%). 
Non-responders to the baseline questionnaire tended to be younger than responders, 
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they were also more likely to be male and live in more deprived areas [26]. The mean 
age of responders was 65.6 years (SD 12.5). 81.5% were male, 73.0% were either 
overweight or obese and 23.4% of the sample drank alcohol on a daily basis (Table 1).  
Mean gout duration was 11.9 years (SD 12.1), 36.8% had experienced 
oligo/polyarticular attacks, 64.5% had experienced at least one attack of gout in the last 
12 months and 56.3% were currently taking allopurinol (Table 2). 
 
Prevalence of anxiety and depression 
Of the baseline questionnaire responders, 1,094 completed the GAD-7. Of these 10.0% 
(n=109) scored above ≥10 and were classified as having generalised anxiety. 1,042 of 
the baseline questionnaire responders had completed the PHQ-9, with 12.6% (n=131) 
scoring above >10 and defined as having depression. 
 
Association between gout characteristics and anxiety and depression 
In crude analysis, compared to those having no gout attacks in the preceding 12 months,  
anxiety (OR 2.67 (95% 1.6 to 4.4)) and depression (3.25 (2.0 to 5.3)) were more 
common in those experiencing ≥3 gout attacks within a 12-month period, but no more 
common in those experiencing only 1-2 attacks (Tables 3 and 4). This association was 
retained for both anxiety and depression after initial adjustment, but was subsequently 
attenuated when adjustment was made for other gout characteristics (anxiety: 1.60 (0.8 
to 3.1); depression 1.83 (0.9 to 3.5)). When frequency of gout attacks was stratified by 
those who used allopurinol and those who did not, there were no associations with 
anxiety. However, there was an association between attack frequency and depression 
amongst those gout patients using allopurinol (2.87 (1.2 to 6.6)).  
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Compared to those with no oligo/polyarticular attacks, those who answered yes were 
significantly more likely to experience anxiety and depression within crude analysis and 
this was retained after adjustment for age, gender and deprivation status. With the 
additional adjustment for BMI, comorbidity and alcohol consumption the association 
between oligo/polyarticular gout and anxiety was lost. However, a history of 
oligo/polyarticular attacks was associated with depression, even after all our 
adjustments (2.01 (1.2 to 3.3)). Furthermore, when stratified, this association was 
retained for both those who were currently using allopurinol (2.64 (1.0 to 6.8)) and 
those who were not (2.09 (1.1 to 4.0)). No associations were found between gout 
duration and the presence of anxiety or depression symptoms at any stage of regression 
analysis.  
 
Discussion 
This primary care-based study examined the prevalence of anxiety and depression in 
people with gout, identifying the association between these psychological 
comorbidities, specific gout characteristics and the role of allopurinol in such 
relationships. We found that 10.0% of gout patients had generalised anxiety and 12.6% 
had depression, as defined by validated diagnostic instruments commonly used in 
primary care. Though there were initial relationships between gout characteristics and 
anxiety, these were attenuated after adjustment. However, certain gout characteristics 
were initially associated with depression and were retained after adjustment. Gout 
patients using allopurinol and experiencing frequent gout attacks over a 12-month 
time-period (≥3), compared with no attacks had nearly a three-fold increase in the odds 
of reporting symptoms of depression. There was also an association between those with 
a history of oligo/polyarticular attacks and depression.  
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To date, evidence about the association between anxiety and depression in patients 
with gout has been limited, particularly in primary care where the majority of patients 
are exclusively managed. Previously Mak et al had reported the prevalence of anxiety 
and depression in gout patients to be 6% and 20%, respectively. Our study found a 
higher prevalence of anxiety (10%) and lower prevalence of depression (13%) which 
may reflect  the different study populations (Singapore vs. England) or the diagnostic 
definitions used for both conditions (GAD-7 and PHQ-9 vs. Hospital Anxiety and 
Depression Scale (HADS)) [27, 28]. In contrast, other research using a large, nationally 
representative US population-based sample to examine depression in different chronic 
disease groups, found gout patients reported a prevalence rate of 13.5% when defined 
through the PHQ-9, comparable to our finding of 12.6%[10]. Our findings are also 
similar to the prevalence of anxiety in the (male) general UK population (8%), but 
slightly higher for depression (13%) [29].  
Though initial associations between the experience of 3≥ gout attacks in 12 months and 
both anxiety and depression were found, and retained after several adjustments, this 
did not remain after adjustment for other gout characteristics. This suggests that gout 
severity, in this case a combination of several poor gout characteristics, influences 
mental health.  In particular, currently experiencing a gout attack has been associated 
with poorer general mental health in gout patients previously [20]. As our findings were 
not maintained after this adjustment, this suggests that though frequently experiencing 
attacks may contribute to some gout patients experiencing anxiety or depression, it 
alone is not enough to lead to these mental health comorbidities.  
Though there was an initial association between oligo/polyarticular gout attacks and 
anxiety, this was attenuated by confounders, including BMI, comorbidity and alcohol 
consumption. As such, anxiety in gout patients experiencing attacks in multiple joints 
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may be primarily related to other health factors. In contrast, the initial odds of gout 
patients who have experienced oligo/polyarticular attacks having depression were 
three-times that of those without multi-joint attacks, even after adjustment this 
association remained.  Our findings concur with previous research which had found a 
correlation between the number of painful joints and poorer general psychological 
health [18].  
As no causal relationship can be established from this cross-sectional analysis, it 
remains unclear whether experiencing these gout characteristics places an additional 
strain on the mental health of gout populations, of which depression may be a 
consequence, or whether depression may result in more severe gout characteristics. 
Both mechanisms are possible, frequently experiencing attacks of gout across multiple 
joints may have negative impacts upon psychosocial factors, such as a reduction in 
social activity, regular absences from work and additional strain on relationships with 
family and friends [30], which may all be association with depressive symptoms. 
Conversely, depressive symptoms could plausibly lead to poor adherence to treatments 
[31] and as such may result in sub-optimal ULT and more frequent gout attacks.  
Allopurinol had a mixed influence on these two gout characteristics. Patients with 
frequent gout attacks who were using allopurinol were 2.87 times more likely to be 
depressed than those experiencing no attacks. However, there was no association 
between frequency of gout attack and depression in those not using allopurinol. Though  
counterintuitive, this result is in-line with Khanna et al who found that 38% of gout 
patients undergoing optimal ULT continued to have ≥2 flares per year and that these 
patients were more likely to have depression [21]. An explanation for such findings may 
be that ULT is being focused on those with the most ‘severe’ gout who are also more 
vulnerable to depression. In comparison, patients with oligo/polyarticular gout, 
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whether they use allopurinol or not, remain over twice as likely to experience 
symptoms of depression as those who experience gout attacks in one joint only.  
These two specific characteristics present a clear sub-group of gout patients who can be 
identified reasonably easily and may benefit either from being managed through ULT, if 
already using ULT, being managed more effectively through regular titration or simply 
being better education on ULT to ensure adherence [32].  
In addition, a future option may be to screen for depression in oligo/polyarticular gout 
patients [33]. In a study of US veterans, people with gout attended mental health clinics 
less frequently than those without gout [17]. This may lead to under-diagnosis of these 
gout-associated mental health comorbidities in a specialist setting. Additional 
identification and subsequent management of depression could result in reduction in 
pain and improvement in physical, as well as psychological health, as previously 
observed in an arthritis population [34]. Benefits of screening may come in two forms, 
the first from improved treatment adherence, as those who have an overall poorer 
health status and who struggle to express emotional problems have reduced adherence 
to treatment for gout [35]. The second benefit may be from decreased cost, with 
depressive comorbidity being a factor in increased costs related to care provision [36]. 
The strengths of this study lie in the examination of a large sample of gout patients from 
primary care and the use of validated tools of psychological morbidity that are widely 
used in this setting and compare well to the diagnostic gold standard (structured 
clinical interview) [23, 37]. Use of these measures, rather than reviewing the medical 
records for previous mental health diagnoses is important as anxiety and depression 
are typically under-reported and under-diagnosed in primary care, with diagnosis often 
only being made when patients consult for other reasons [38]. 
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Limitations of this work include a potential response bias. Only a selection of gout 
characteristics was examined, there would have also been benefit in examining the 
association between the presence of tophi, serum uric acid levels or time with pain 
between attacks of gout and anxiety and depression, but this information was either not 
originally included at baseline, or where available was insufficiently reported. 
In conclusion, 1 in 10 gout patients attending UK primary care will also have anxiety or 
depression symptoms. This is a high proportion of patients when compared to male UK 
primary care patients of a similar age (60-69 years), where prevalence of anxiety and 
depression is estimated at 4.6% and 6.5% respectively [39, 40]. However, though 
anxiety may present periodically in gout patients during an attack, it is depression 
which is associated with particular gout characteristics. In particular, patients who 
experience attacks in more than one joint are particularly vulnerable to experiencing 
depression. In addition to the subsequent negative influence of depression on the 
psychological health of the gout patient, the presence of depression may also influence 
adherence to gout medication and participation in routine reviews and hence impact 
adversely on the outcome of gout management. Whilst there is currently insufficient 
evidence to support the routine screening of patients with gout for depression, 
clinicians should be aware that gout and depression often coexist and as this may 
adversely impact on health outcomes they should take a more aggressive approach to 
the treatment of this sub-group of gout patients.  
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Table 1: Characteristics of gout patients (n = 1,184).  
 Frequency  
n (%) 
  
Age (mean, SD) 65.6 (12.5) 
Gender (Male %) 990 (83.6) 
Neighbour Deprivation Status (Tertiles)  
 Least deprived 384 (32.4) 
 Mid-deprived 398 (33.6) 
 Most deprived 402 (34.0) 
BMI (kg/m2)  
 <25.0  221 (19.8) 
 25.0-29.9 511 (45.7) 
 30.0-34.9 260 (23.2) 
 ≥35.0 127 (11.4) 
Alcohol consumption  
 Daily/almost daily 273 (23.4) 
 3-4 times per week 263 (22.5) 
 1-2 times per week 254 (21.8) 
 1-3 times per month 109 (9.3) 
 Occasionally 155 (13.3) 
 Never 113 (9.7) 
Comorbidity  
 Hypertension 731 (61.7) 
 Hyperlipidaemia 508 (42.9) 
 Diabetes mellitus 205 (17.3) 
 Angina 147 (12.4) 
 Myocardial infarction 119 (10.0) 
 Kidney stones 81 (6.8) 
 Transient ischaemic attack 62 (5.2) 
 Kidney failure 56 (4.7) 
 Stroke 37 (3.1) 
Figures are n (%) unless otherwise stated.  
SD: Standard Deviation, BMI: Body Mass Index 
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Table 2: Gout-specific characteristics.  
Characteristics  Frequency 
n (%) 
  
Gout duration (n = 1,095) (mean years, SD) 11.9 (12.1) 
Gout attack(s) in last 12 months (n = 1,123)  
 0 398 (35.4) 
 1-2 418 (37.2) 
 ≥3 307 (27.3) 
Currently experiencing a gout attack (n = 1,135)  
 No 1,003 (88.4) 
 Yes 132 (11.6) 
Currently using Allopurinol (n = 1,120)  
 No 490 (43.7) 
 Yes 630 (56.3) 
Ever experienced gout in more than one joint (n = 1,131)   
 No 695 (61.5) 
 Yes 436 (38.5) 
Figures are n (%) unless otherwise stated 
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Table 3: Association between anxiety and gout characteristics 
 
 Anxiety  Crude OR 
(95% CI) 
Adjusted OR (95% CI)  Adjusted OR (95% CI),  
stratified by use of allopurinol 
 No (%) 
 
Yes (%)   Age, gender &  
deprivation status 
Age, gender,  
deprivation status,  
BMI, comorbidity, 
alcohol consumption 
& gout characteristics 
 No  Yes 
Frequency of  
gout attacks 
         
 0 347 (93) 26 (7)  Ref Ref Ref  Ref Ref 
 1-2 355 (92) 29 (8)  1.09 (0.6 to 1.9) 0.95 (0.5 to 1.7) 0.68 (0.4 to 1.3)  0.57 (0.2 to 1.8) 0.76 (0.3 to 1.8) 
 3≥ 240 (83) 48 (17)  2.67 (1.6 to 4.4)* 2.23 (1.3 to 3.7)* 1.60 (0.8 to 3.1)  2.07 (0.6 to 7.4) 1.72 (0.7 to 4.3) 
          
Oligo/ 
polyarticular  
gout 
         
 No 595 (92) 53 (8)  Ref Ref Ref  Ref Ref 
 Yes 351 (87) 51 (13)  1.63 (1.1 to 2.4)* 1.53 (1.0 to 2.3)* 0.96 (0.6 to 1.6)  1.04 (0.4 to 3.0) 0.94 (0.5 to 1.9) 
          
Gout duration  
(years) 
         
 ≤2  248 (89) 31 (11)  Ref Ref Ref  Ref Ref 
 3-8 232 (91) 23 (9)  0.79 (0.4 to 1.4) 0.86 (0.5 to 1.5) 0.74 (0.4 to 1.5)  0.57 (0.2 to 1.6) 0.96 (0.3 to 3.3) 
 9-17 196 (92) 17 (8)  0.69 (0.4 to 1.3) 0.85 (0.4 to 1.6) 0.87 (0.4 to 1.8)  0.34 (0.1 to 1.4) 1.90 (0.6 to 6.3) 
 18≥ 243 (88) 32 (12)  1.05 (0.6 to 1.8) 1.51 (0.8 to 2.7) 1.48 (0.7 to 3.0)  0.77 (0.2 to 3.1) 2.99 (0.9 to 9.8) 
* = p ≤0.05 
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Table 4: Association between depression and gout characteristics  
 
 Depression  Crude OR 
(95% CI) 
Adjusted OR (95% CI)  Adjusted OR (95% CI),  
stratified by use of allopurinol 
 No (%) 
 
Yes (%)   Age, gender &  
deprivation status 
Age, gender,  
deprivation status,  
BMI, comorbidity, 
alcohol consumption 
& gout characteristics  
 No  Yes 
Frequency of  
gout attacks 
         
 0 333 (92) 28 (8)  Ref Ref Ref  Ref Ref 
 1-2 325 (89) 39 (11)  1.43 (0.9 to 2.4) 1.33 (0.8 to 2.2) 1.03 (0.6 to 1.9)  0.64 (0.2 to 1.9) 1.49 (0.7 to 3.4) 
 3≥ 212 (79) 58 (21)  3.25 (2.0 to 5.3)* 2.95 (1.8 to 4.8)* 1.83 (0.9 to 3.5)  1.16 (0.3 to 4.1) 2.87 (1.2 to 6.6)* 
          
Oligo/ 
polyarticular  
gout 
         
 No 565 (92) 50 (8)  Ref Ref Ref  Ref Ref 
 Yes 308 (80) 75 (20)  2.75 (1.9 to 4.0)* 2.70 (1.8 to 4.0)* 2.01 (1.2 to 3.3)*  2.64 (1.0 to 6.8)* 2.09 (1.1 to 4.0)* 
          
Gout duration  
(years) 
         
 ≤2  230 (87) 34 (13)  Ref Ref Ref  Ref Ref 
 3-8 222 (89) 27 (11)  0.82 (0.5 to 1.4) 0.83 (0.5 to 1.4) 0.65 (0.3 to 1.2)  0.46 (0.2 to 1.3) 1.27 (0.4 to 3.8) 
 9-17 176 (89) 22 (11)  0.85 (0.5 to 1.5) 0.95 (0.5 to 1.7) 0.87 (0.4 to 1.7)  0.45 (0.1 to 1.7) 2.11 (0.7 to 6.4) 
 18≥ 223 (85) 38 (15)  1.15 (0.7 to 1.9) 1.33 (0.8 to 2.2) 1.12 (0.6 to 2.2)  0.92 (0.3 to 3.2) 2.11 (0.7 to 6.3) 
* = p ≤0.05 
 
